Vector vaccines: How effective they are on virus variants

Vector vaccines: How effective they are on virus variants

In Germany, the British mutation has almost completely replaced the original corona virus. In addition to the alpha variant B.1.1.7, the gamma and beta mutations are also in circulation. In addition, another mutation (Delta) spread quickly, first in India and then in England, and is now also on the rise in Germany. So how effective are the vector vaccines from AstraZeneca and Johnson & Johnson against the new virus variants?

The vector vaccines from  AstraZeneca  and  Johnson  & Johnson are generally highly effective against severe corona courses. This is how the vaccines against the virus variants do.

This is how effective the AstraZeneca vaccine is for virus variants

The  corona vaccine  protects between 60 and 79 percent against severe courses. The AstraZeneca vaccine is effective against the virus variants:

  • Alpha variant (B.1.1.7):  The vaccine from AstraZeneca was initially vaccinated in Great Britain in particular and shows only a slightly weakened effectiveness compared to the original variant of the virus. With around 70 percent, the vaccine offers sufficient protection against severe courses.
  • Beta variant (B.1.351):  The vaccine from AstraZeneca is not sufficient  against the South African variant of the  coronavirus . The vector vaccine only achieves a low effectiveness of 21 percent.
  • Gamma variant (P.1):  As with the alpha variant, the vaccine from AstraZeneca has only a slightly reduced effectiveness against severe courses.
  • Delta variant (B.1.617):  With an efficacy of 60 percent, the vaccine from AstraZeneca also protects against the newer mutation from India.

Johnson & Johnson: That’s how effective the vaccine is for mutations

The vaccine from Johnson & Johnson has a protective effect of 66 percent and can prevent severe courses by 85 percent. This is how effective the vaccine from Johnson & Johnson is against the virus variants:

  • Alpha variant (B.1.1.7):  The effect of the vaccine from Johnson & Johnson is only slightly weakened compared to the alpha variant B.1.1.7 and offers sufficient vaccination protection against severe courses.
  • Beta variant (B.1.351):  Initial studies show that the vector vaccine from Johnson & Johnson is also effective against the virus variant B.1.351. With around 64 percent effectiveness, the vaccine protects against severe disease progression.
  • Gamma variant (P.1):  In Brazil, the vaccine shows an efficacy of 68 percent.
  • Delta variant (B.1.617):  According to information from Johnson & Johnson, the vaccine also shows a neutralizing effect against the delta variant and can therefore reliably protect against a severe course.

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *